ABSTRACT
Background Herpes simplex encephalitis (HSE) is the most common form of sporadic encephalitis which is caused by herpes simplex virus type 1 (HSV-1). Current guidelines recommend intravenous Acyclovir for 14–21 days in cases of HSE.
Objectives Optimizing the Acyclovir treatment duration is important in regards to preventing Acyclovir-related neurotoxicity and nephrotoxicity.
Study design We retrospectively evaluated 13 patients, who were diagnosed with HSE by molecular testing (HSV-1 PCR positivity in cerebrospinal fluid), in two university hospitals in Istanbul, between 2010 and 2021. The patients were treated either 10 days or less as a short-term treatment regimen of Acyclovir or for 14 days or more as long-term treatment regimen
Results The median age was 58 years (range 24–82 years) and 54% of them were male. The median follow-up time was 79 days (range 20-670 days) after discharge. Long-term treatment was used in 6 and a short-term treatment regimen was used in 7 cases. One of the patients died on the 4th day of Acyclovir treatment. One patient never received Acyclovir treatment. Of the 5 patients who received long-term treatment, 3 (21-28 days) had amnesia and orientation-cooperation restriction, one (21 days) died on the 2nd day of treatment, while the other (14 days) had no sequelae. There were no sequelae in three out of 5 patients who received short-term treatment.
Conclusions We believe that it is necessary to determine the optimal Acyclovir therapy duration should be evaluated in a prospective randomized clinical trial in large patient population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All data produced in the present study are available upon reasonable request to the authors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee approval was obtained from the ethics committee of Istanbul Medeniyet University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data availability : If request it will be sent to the editors
Conflicts of Interest and Source of Funding: Authors have no competing interests to declare and not received any fund.
Ethics approval statement: Ethics committee approval was obtained from the ethics committee of Istanbul Medeniyet University.
Patient consent statement: In tertiary hospitals at Turkey, all admitted patients sign the consent form to publish their medical knowledge for scientific purposes.
Ferhat Arslan: Conceptualization, Methodology, Writing- Original draft preparation. Ravza Akgündüz: Data curation, Investigation. Abdülkadir Ermiş: Data curation, Investigation. Begüm Bektaş: Data curation: Ebru Erbayat: Writing- Reviewing and Editingi, Haluk Vahaboğlu:Supervision
Data Availability
All data produced in the present study are available upon reasonable request to the authors
